Navigation Links
Protalix BioTherapeutics, Inc. Receives Approval from the FDA to,Initiate a Phase III Clinical Trial of prGCD

Protalix BioTherapeutics, Inc.

Protalix's proprietary technology is based on its plant cell culture and bioreactor system, which provides an effective and scaleable cell system for industrial production of recombinant biopharmaceuticals. Protalix is pursuing advanced clinical studies for its enzyme therapy for Gaucher Disease and intends to advance additional recombinant biopharmaceutical drug development programs. The Company believes its plant-based expression has significant advantages over more traditional mammalian and bacterial expression technology with respect to patient safety, cost and scalability.

Safe Harbor Statement

To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, the inherent risks and uncertainties in developing drug platforms and products of the type we are developing; delays in our preparation and filing of applications for regulatory approval; delays in the approval or potential rejection of any applications we file with the FDA, or other health regulatory authorities; lack of progress of our research and development (including the results of clinical trials being conducted by us); obtaining on a timely basis sufficient patient enrollment in our clinical trials; the impact of development of competing therapies and/or technologies by other companies; our ability to obtain additional financings required to fund our research programs; our
'"/>




Page: 1 2 3

Related medicine technology :

1. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
2. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
3. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
4. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
5. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:6/17/2013)... Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... ENDO 2013, the Endocrine Society,s 95 th ... both melatonin and cortisol rhythms. This effect further ... clock and address the circadian desynchrony which is ... and Efficacy of Tasimelteon) and RESET (Randomized-withdrawal study ...
(Date:6/17/2013)... 17, 2013 Valeant Pharmaceuticals International, Inc. (NYSE: ... has filed a preliminary prospectus supplement to its effective shelf ... similar filing with securities regulatory authorities in each of the ... a public offering of its common shares to raise gross ... Company will also grant to the underwriters of the Offering ...
(Date:6/17/2013)... June 17, 2013 The following is a Statement ... at Drugfree.org :   Last Friday, ... was halting the sale of prescription drug paraphernalia products. The ... that from time to time there may be individual items ... As a result of this misinterpretation we are electing to ...
Breaking Medicine Technology:Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 2Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 3Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 4Valeant Pharmaceuticals Announces Public Offering Of Common Shares 2Valeant Pharmaceuticals Announces Public Offering Of Common Shares 3Valeant Pharmaceuticals Announces Public Offering Of Common Shares 4A Win for Families: Urban Outfitters Halts Prescription Drug Paraphernalia Product Sales 2
... it has been selected as a Finalist ... list honoring the year,s most promising private technology ventures ... The Red Herring editorial team selected the most innovative ... America. The nominees are evaluated on both quantitative and ...
... a full-service pharmacy benefit management and ancillary medical ... Craig Rollins has joined the organization as Vice ... role he will be responsible for the strategic ... 1Click Ancillary online marketplace. myMatrixx launched 1Click Ancillary ...
Cached Medicine Technology:DICOM Grid Selected as a Finalist for the 2012 Red Herring Top 100 Americas Award 2myMatrixx Names Craig Rollins, Vice President of Ancillary and Business Development 2
(Date:6/17/2013)... Vince Del Monte and Ben Pakulski are running a ... and it will only be around for the next 4 days. ... has released an updated Hypertrophy Max review to help people understand ... review here . , Davids says, "Vince Del Monte and Ben ... day sale as an extra incentive for people to take action. ...
(Date:6/17/2013)... helped to boost organ donor registration rates, according to ... of Transplantation . The findings suggest that social media ... of problems related to public health in which communication ... in the United States have remained static while increasing ... To provide organs to the more than 100,000 patients ...
(Date:6/17/2013)... Nearly 26 million adults have diabetes in ... adults are estimated to have pre-diabetes. The physicians' at ... through weight loss and lifestyle changes. Losing just 5 ... sugar level back within the normal range. Taking into ... Loss physicians can help tailor a diabetes diet plan ...
(Date:6/17/2013)... Park City, Utah (PRWEB) June 17, 2013 ... information on stand-alone HRAs for small businesses ... alternatives to traditional employer sponsored health benefits, is ... health reimbursement arrangements . , According to ... called Health Reimbursement Accounts or HRAs, offer small ...
(Date:6/17/2013)... Chile (PRWEB) June 17, 2013 Ayurveda ... means in sanscrit "knowledge or wisdom of life." As a ... spirit and the transformation of consciousness. Its fundamental philosophy is ... harmony with our environment. In order to re-establish optimal health, ... and then adopt a life style which brings us back ...
Breaking Medicine News(10 mins):Health News:Updated Hypertrophy Max Review Released for Vince Del Monte and Ben Pakulski's Hypertrophy Max Training Program 2Health News:Social media initiative may help increase organ donations 2Health News:Best Diet Plans for Diabetics; Tips from 101 Medical Weight Loss 2Health News:Best Diet Plans for Diabetics; Tips from 101 Medical Weight Loss 3Health News:Best Diet Plans for Diabetics; Tips from 101 Medical Weight Loss 4Health News:Zane Benefits Publishes New Information on Stand-Alone HRAs for Small Businesses 2Health News:Ayurveda Chile Program Offered by Escuela Ayurveda de California in August, 2013 2
... Seagull Technology,Pty Ltd, has developed a non-invasive drug delivery ... Australia,s leading cause of,blindness and severe vision loss -- ... retina which affects one in seven people over,the age ... ultrasound (sound,waves) in a handheld device to send drugs ...
... the largest,provider of business services to orthodontic and ... by adding an experienced,marketing professional to its team. ... will work out of the company,s,Metairie office., ... our team to,provide our doctors creative cutting edge ...
... Runyon Cancer Research Foundation named 14 new Damon ... Committee review. The recipients of this prestigious, ... and translational cancer research in the laboratories of ... Fellowship is specifically intended to encourage the nation,s ...
... a woman,s eggs to deteriorate in quality with age, and ... choose an egg -- out of a stash of roughly ... the ovary be influenced to pick a "good" quality egg ... questions are much on the mind of fertility researcher Teresa ...
... vessels, researchers say , , THURSDAY, June 19 (HealthDay News) ... role in allowing experts to see the many reds, ... a report by researchers at the Massachusetts Institute of ... minor players in brain activity, receive signals directly from ...
... We Make A Life By What We Give is the ... about their lives and how they can share what they have ... and Riley Hospital for Children physician-philosopher Richard B. Gunderman, M.D., Ph.D. ... giving in their lives. , In the book, Dr. Gunderman expands ...
Cached Medicine News:Health News:Revolutionary Therapy: Needle-Free Technology for the Treatment Of Blinding Eye Disease 2Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 14 top young investigators 2Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 14 top young investigators 3Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 14 top young investigators 4Health News:New photo 'op' for ovaries may solve some mysteries of infertility 2Health News:Star-Shaped Brain Cells Make Scans Possible 2
... magnification and increased stereopsis, the Central Retinal ... to the equatorial regions. The Central Retinal ... in membrane peeling in proliferative vitreoretinopathy extending ... The ACS Vitrectomy Lenses from Volk can ...
... These patented ACS lenses offer the ... view as the original clariVits. The simple ... while maintaining its integrity during surgery. Simply ... contact element, then lock together for use. ...
... magnification, indirect, contact, vitrectomy lens available! ... the surgical management of macular holes, ... submacular surgery. The magnification of the ... of a plano/concave direct imaging vitrectomy ...
... XL is recommended for evaluating ... fundus and in the management ... the ideal lens for small ... operating microscope. It provides a ...
Medicine Products: